ResMed (RMD) Earnings Date, Estimates & Call Transcripts $247.33 +3.55 (+1.46%) (As of 02:15 PM ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ResMed Latest Earnings SummaryUpcoming Q2 Earnings DateJan. 22EstimatedActual EPS (Oct. 24) $2.20 Beat By $0.17 Consensus EPS (Oct. 24) $2.03 ResMed posted Q1 2025 earnings on October 24, 2024, reporting an EPS of $2.20, which beat the consensus estimate of $2.03 by $0.17. Quarterly revenue rose 11.1% year-over-year to $1.22 billion, above analysts' expectations of $1.19 billion. With a trailing EPS of $7.55 and a P/E Ratio of 32.76, ResMed's earnings are expected to grow 8.30% next year, from $9.28 to $10.05 per share. Conference Call TranscriptConference Call AudioEarnings Press ReleaseEarnings Slide DeckSEC 10-Q/10-K FilingRMD Upcoming EarningsResMed's next earnings date is estimated for Wednesday, January 22, 2025, based off prior year's reporting schedules. Get ResMed Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ResMed and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataRMD Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.RMD Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover ResMed Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20243$1.59$1.66$1.63Q2 20243$1.74$1.79$1.77Q3 20243$1.87$1.92$1.89Q4 20243$1.92$2.00$1.96FY 202412$7.12$7.37$7.25Q1 20252$1.93$2.02$1.98Q2 20252$2.06$2.24$2.15Q3 20252$2.27$2.33$2.30Q4 20252$2.34$2.43$2.39FY 20258$8.60$9.02$8.81Q1 20261$2.25$2.25$2.25Q2 20261$2.32$2.32$2.32Q3 20261$2.47$2.47$2.47Q4 20261$2.48$2.48$2.48FY 20264$9.52$9.52$9.52Q1 20271$2.44$2.44$2.44 ResMed Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 1/22/2025(Estimated)------- 10/24/2024Q1 2025$2.03$2.20+$0.17$2.29$1.19B$1.22B 8/1/2024Q4 2024$2.03$2.08+$0.05$2.18$1.22B$1.20B 4/25/2024Q3 2024$1.91$2.13+$0.22$2.22$1.17B$1.20B 1/24/2024Q2 2024$1.81$1.88+$0.07$2.34$1.15B$1.16B 10/26/2023Q1 2024$1.63$1.64+$0.01$1.79$1.10B$1.10B 8/3/2023Q4 2023$1.67$1.60 -$0.07$1.64$1.14B$1.12B Download Our Tesla Ebook For Free (Ad)Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link.4/27/2023Q3 2023$1.58$1.68+$0.10$1.78$1.05B$1.12B 1/26/2023Q2 2023$1.62$1.66+$0.04$1.79$996.22M$1.03B ResMed Earnings - Frequently Asked Questions When is ResMed's earnings date? ResMed has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, January 22nd, 2025 based off last year's report dates. Learn more on RMD's earnings history. Did ResMed beat their earnings estimates last quarter? In the previous quarter, ResMed (NYSE:RMD) reported $2.20 earnings per share (EPS) to beat the analysts' consensus estimate of $2.03 by $0.17. Learn more on analysts' earnings estimate vs. RMD's actual earnings. How can I listen to ResMed's earnings conference call? The conference call for ResMed's latest earnings report can be listened to online. Listen to Conference Call How can I read ResMed's conference call transcript? The conference call transcript for ResMed's latest earnings report can be read online. Read Transcript How can I view ResMed's earnings report? ResMed's earnings report can be found in their filing with the SEC. View SEC filing How much revenue does ResMed generate each year? ResMed (NYSE:RMD) has a recorded annual revenue of $4.69 billion. How much profit does ResMed generate each year? ResMed (NYSE:RMD) has a recorded net income of $1.02 billion. RMD has generated $7.55 earnings per share over the last four quarters. What is ResMed's price-to-earnings ratio? ResMed (NYSE:RMD) has a trailing price-to-earnings ratio of 32.57 and a forward price-to-earnings ratio of 26.50. The price/earnings-to-growth ratio is 1.77. What is ResMed's EPS forecast for next year? ResMed's earnings are expected to grow from $9.28 per share to $10.05 per share in the next year, which is a 8.30% increase. ` More Earnings Resources from MarketBeat Related Companies Boston Scientific Earnings Medtronic Earnings Becton, Dickinson and Company Earnings Edwards Lifesciences Earnings IDEXX Laboratories Earnings DexCom Earnings STERIS Earnings Insulet Earnings Hologic Earnings Baxter International Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings Report Has Trump Finally Gone Too Far? (Ad)Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover This page (NYSE:RMD) was last updated on 11/25/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ResMed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ResMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
